Li H, Oehrlein S A, Wallerath T, Ihrig-Biedert I, Wohlfart P, Ulshöfer T, Jessen T, Herget T, Förstermann U, Kleinert H
Department of Pharmacology, Johannes Gutenberg University, Mainz, Germany.
Mol Pharmacol. 1998 Apr;53(4):630-7. doi: 10.1124/mol.53.4.630.
In primary human umbilical vein endothelial cells (HUVECs), incubation with phorbol-12-myristate-13-acetate (PMA) enhanced basal and bradykinin-stimulated nitric oxide production. In the HUVEC-derived cell line EA.hy 926, PMA and phorbol-12,13-dibutyrate stimulated endothelial nitric oxide synthase (NOS III) mRNA expression in a concentration- and time-dependent manner. Maximal mRNA expression (3.3-fold increase) was observed after 18 hr. NOS III protein and activity were increased to a similar extent. The specific protein kinase C (PKC) inhibitors bisindolylmaleimide I (1 microM), Gö 6976 [12-(2 cyanoethyl)-6,7,12, 13-tetrahydro-13-methyl-5-oxo-5H-indolo[2,3-a]pyrrolo-[3, 4-c]carbazole] (1 microM), Ro-31-8220 [3-[1-[3(amidinothio)propyl-1H-inoyl-3-yl]3-(1-methyl-1H- indoyl-3-yl) maleimide methane sulfonate] (1 microM), and chelerythrine (3 microM) did not change NOS III expression when applied alone, but they all prevented the up-regulation of NOS III mRNA produced by PMA. Of the PKC isoforms expressed in EA.hy 926 cells (alpha, beta I, delta, epsilon, eta, zeta, lambda, and mu), only PKC alpha and PKC epsilon showed changes in protein expression after PMA treatment. Incubation of EA.hy 926 cells with PMA for 2-6 hr resulted in a translocation of PKC alpha and PKC epsilon from the cytosol to the cell membrane, indicating activation of these isoforms. After 24 hr of PMA incubation, both isoforms were down-regulated. The time course of activation and down-regulation of these two PKC isoforms correlated well with the PMA-stimulated increase in NOS III expression. When human endothelial cells (ECV 304 or EA.hy 926) were transiently or stably transfected with a 3.5-kb fragment of the human NOS III promoter driving a luciferase reporter gene, PMA stimulated promoter activity up to 2.5-fold. On the other hand, PMA did not change the stability of the NOS III mRNA. These data indicate that stimulation of PKC alpha, PKC epsilon, or both by active phorbol esters represents an efficacious pathway activating the human NOS III promoter in human endothelium.
在原代人脐静脉内皮细胞(HUVECs)中,与佛波醇-12-肉豆蔻酸酯-13-乙酸酯(PMA)共同孵育可增强基础状态下以及缓激肽刺激后的一氧化氮生成。在源自HUVECs的细胞系EA.hy 926中,PMA和佛波醇-12,13-二丁酸酯以浓度和时间依赖性方式刺激内皮型一氧化氮合酶(NOS III)mRNA表达。18小时后观察到最大mRNA表达量(增加3.3倍)。NOS III蛋白和活性也有类似程度的增加。特异性蛋白激酶C(PKC)抑制剂双吲哚基马来酰亚胺I(1 microM)、Gö 6976 [12-(2-氰基乙基)-6,7,12,13-四氢-13-甲基-5-氧代-5H-吲哚并[2,3-a]吡咯并[3,4-c]咔唑](1 microM)、Ro-31-8220 [3-[1-[3-(脒硫基)丙基-1H-吲哚-3-基]-3-(1-甲基-1H-吲哚-3-基)马来酰亚胺甲磺酸盐](1 microM)和白屈菜红碱(3 microM)单独应用时不改变NOS III表达,但它们均能阻止PMA诱导的NOS III mRNA上调。在EA.hy 926细胞中表达的PKC同工型(α、βI、δ、ε、η、ζ、λ和μ)中,只有PKCα和PKCε在PMA处理后蛋白表达发生变化。将EA.hy 926细胞与PMA孵育2 - 6小时导致PKCα和PKCε从胞质溶胶转位至细胞膜,表明这些同工型被激活。PMA孵育24小时后,两种同工型均下调。这两种PKC同工型的激活和下调时间进程与PMA刺激的NOS III表达增加密切相关。当用人内皮细胞(ECV 304或EA.hy 926)瞬时或稳定转染驱动荧光素酶报告基因的人NOS III启动子的3.5 kb片段时,PMA刺激启动子活性高达2.5倍。另一方面,PMA不改变NOS III mRNA的稳定性。这些数据表明,活性佛波醇酯对PKCα、PKCε或两者的刺激代表了一种在人内皮中激活人NOS III启动子的有效途径。